BCR-ABL isoforms associated with intrinsic or acquired resistance to imatinib: more heterogeneous than just ABL kinase domain point mutations?

[1]  G. Superti-Furga,et al.  Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia , 2008, Leukemia.

[2]  M. A. Moreira,et al.  A recurrent splicing variant without c-ABL Exon 7 in Imatinib-resistant patients. , 2008, Leukemia research.

[3]  Martin C. Müller,et al.  Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib , 2008, Haematologica.

[4]  Jorge Cortes,et al.  Flying under the radar: the new wave of BCR–ABL inhibitors , 2007, Nature Reviews Drug Discovery.

[5]  G. Perrone,et al.  Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches. , 2007, Cancer research.

[6]  M. Baccarani,et al.  Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. , 2007, Haematologica.

[7]  C. Preudhomme,et al.  The prognosis impact of BCR-ABL P-loop mutations: worse or not worse? , 2007, Leukemia.

[8]  J. Melo,et al.  Abnormally Small BCR-ABL Transcripts in CML Patients before and during Imatinib Treatment. , 2006 .

[9]  H. Kantarjian,et al.  Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate , 2006, Leukemia.

[10]  Ingo Roeder,et al.  Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications , 2006, Nature Medicine.

[11]  I. Mikkola,et al.  A novel Bcr-Abl splice isoform is associated with the L248V mutation in CML patients with acquired resistance to imatinib , 2006, Leukemia.

[12]  Francisco Cervantes,et al.  Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. , 2006, Blood.

[13]  C. Sawyers,et al.  Treating Imatinib-Resistant Leukemia: The Next Generation Targeted Therapies , 2006, TheScientificWorldJournal.

[14]  J. Cayuela,et al.  Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(ϕ)-LMC GROUP) , 2006, Leukemia.

[15]  T. Lamark,et al.  Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL , 2005, Leukemia.

[16]  R. Herrmann,et al.  Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. , 2004, Blood.

[17]  M. Baccarani,et al.  Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib. , 2004, Clinical chemistry.

[18]  H. Cavé,et al.  Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program , 2003, Leukemia.

[19]  Susan Branford,et al.  Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. , 2003, Blood.

[20]  C. Peschel,et al.  Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back , 2003, Leukemia.

[21]  J. Kuriyan,et al.  Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. , 2002, Cancer cell.

[22]  R. Herrmann,et al.  High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. , 2002, Blood.

[23]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[24]  P. Erben,et al.  Resistance to targeted therapy in chronic myelogenous leukemia. , 2007, Seminars in hematology.

[25]  I. Glauche,et al.  Pathogenesis, treatment effects, and resistance dynamics in chronic myeloid leukemia - insights from mathematical model analyses , 2007, Journal of Molecular Medicine.

[26]  T. Hughes,et al.  Detection of BCR-ABL mutations and resistance to imatinib mesylate. , 2006, Methods in molecular medicine.

[27]  M. Baccarani,et al.  New tyrosine kinase inhibitors in chronic myeloid leukemia. , 2005, Haematologica.

[28]  B. Druker,et al.  Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy , 2002, Leukemia.

[29]  J. Melo,et al.  An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. , 1994, Leukemia.